Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Adherence and persistence to long-acting injectable dopamine receptor blocking agent therapy in the United States: A systematic review and meta-analysis of cohort studies.

Tytuł:
Adherence and persistence to long-acting injectable dopamine receptor blocking agent therapy in the United States: A systematic review and meta-analysis of cohort studies.
Autorzy:
Lee S; Department of Clinical Sciences, High Point University Fred Wilson School of Pharmacy, High Point, NC, USA.
Schwartz S; Department of Clinical Sciences, High Point University Fred Wilson School of Pharmacy, High Point, NC, USA. Electronic address: .
Źródło:
Psychiatry research [Psychiatry Res] 2021 Dec; Vol. 306, pp. 114277. Date of Electronic Publication: 2021 Nov 13.
Typ publikacji:
Journal Article; Meta-Analysis; Review; Systematic Review
Język:
English
Imprint Name(s):
Publication: Limerick : Elsevier/North-Holland Biomedical Press
Original Publication: Amsterdam, Elsevier/North-Holland Biomedical Press.
MeSH Terms:
Antipsychotic Agents*/therapeutic use
Dopamine Antagonists*/therapeutic use
Schizophrenia*/drug therapy
Delayed-Action Preparations/therapeutic use ; Humans ; Medication Adherence ; Observational Studies as Topic ; Receptors, Dopamine ; United States
Contributed Indexing:
Keywords: Antipsychotic; Continuation; Discontinuation; Naturalistic; Observational
Substance Nomenclature:
0 (Antipsychotic Agents)
0 (Delayed-Action Preparations)
0 (Dopamine Antagonists)
0 (Receptors, Dopamine)
Entry Date(s):
Date Created: 20211122 Date Completed: 20220328 Latest Revision: 20220531
Update Code:
20240105
DOI:
10.1016/j.psychres.2021.114277
PMID:
34808495
Czasopismo naukowe
The purpose of this systematic review and meta-analysis was to assess adherence and persistence to long-acting injectable dopamine receptor blocking agents (LAI DRBAs) in published observational cohort studies conducted in the United States. Adherence rate (proportion of days covered ≥80%) and persistence rate (no gap in therapy ≥60 days) to LAI DRBAs were examined in 26 articles for qualitative review and 8 articles for quantitative review. There was significant variability in adherence and persistence rates to LAI DRBAs in the reported observational cohort studies. The mean adherence and persistence rates to LAI DRBAs in the included studies were 36% (8-66%) and 56% (32-80%), respectively. The use of LAI DRBAs showed cumulative benefit of achieving adherence 1.40 times higher compared to oral agents. The persistence rate was measured by number of patients having no more than 60 days gap in therapy at follow-up, and the cumulative benefit of being persistently on the therapy was 1.65 times higher among the LAI agents-exposed group compared to the oral agents-exposed group. The use of LAI DRBAs confers benefit in adherence and persistence compared to oral DRBA formulations.
(Copyright © 2021 Elsevier B.V. All rights reserved.)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies